American Capital Management Inc. increased its position in Cambrex Corporation (NYSE:CBM) by 11.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 507,888 shares of the biotechnology company’s stock after buying an additional 53,780 shares during the period. Cambrex Corporation accounts for about 1.9% of American Capital Management Inc.’s holdings, making the stock its 21st largest position. American Capital Management Inc. owned about 1.56% of Cambrex Corporation worth $30,346,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Flinton Capital Management LLC raised its position in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares during the last quarter. Creative Planning raised its position in Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares during the last quarter. YorkBridge Wealth Partners LLC raised its position in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new position in Cambrex Corporation during the first quarter worth approximately $109,000. 98.28% of the stock is owned by hedge funds and other institutional investors.
Shares of Cambrex Corporation (NYSE CBM) opened at 51.40 on Friday. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 18.72 and a beta of 2.28. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95. The company’s 50-day moving average price is $57.39 and its 200 day moving average price is $55.47.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting the consensus estimate of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The business had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same quarter in the prior year, the firm earned $0.68 EPS. The business’s revenue was up 13.4% on a year-over-year basis. On average, analysts predict that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by BNB Daily and is owned by of BNB Daily. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/american-capital-management-inc-purchases-53780-shares-of-cambrex-corporation-cbm-updated-updated.html.
A number of equities analysts have recently commented on the company. BidaskClub lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Zacks Investment Research lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Finally, ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $64.00.
In other Cambrex Corporation news, VP Samantha Hanley sold 14,000 shares of the stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $57.56, for a total transaction of $805,840.00. Following the completion of the transaction, the vice president now owns 1,500 shares of the company’s stock, valued at approximately $86,340. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $54.19, for a total transaction of $650,280.00. Following the transaction, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $5,165,824.32. The disclosure for this sale can be found here. Insiders have sold a total of 70,656 shares of company stock valued at $4,064,423 in the last three months. Insiders own 2.48% of the company’s stock.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.